Upper Tract Urothelial Carcinoma
Advertisement
Surgical resection of the primary tumor can provide survival benefits in certain patients with metastatic UTUC.
Drs. Roupret and Houede dissect their research on the safety and efficacy of durvalumab with NAC for operable high-risk UTUC.
Dr. Murray and Laura Bauer share their experiences treating patients with UTUC using mitomycin gel.
Patients who achieved a complete response after six doses of UGN-101 were followed up for 12 months after initial CR.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Drs. Michael Whalen and Vincent Xu discuss potential alternative treatments for patients who are ineligible for chemotherapy.
Drs. Michael Whalen and Vincent Xu discuss their recent analysis of neoadjuvant chemotherapy utilization for UTUC.
Drs. Sundaram and Murray highlight the results of a study on robotic nephroureterectomy and bladder cuff excision for UTUC.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
NLR can be a prognostic predictor of clinicopathology in UTUC, aiding risk stratification and management.
A meta-analysis sought to determine the surgical and oncological outcomes of LNU and ONU in patients with UTUC.
For patients with UTUC, bladder cuff excision and radical nephroureterectomy is a longstanding treatment.
The study’s data set included abstracted clinical data with germline and tumor genomic data.
Patients with localized UTUC have high unmet needs and tumors with a high frequency of FGFR3 alterations.
Drs. Packiam and Murray weigh multiple studies exploring gemcitabine/docetaxel as a frontline therapy for UTUC.
Drs. Margulis and Murray showcase the ENLIGHTED study examining the efficacy and safety of padeliporfin VTP for LG UTUC.
Dr. Moussa provides an overview of his research on prognostic factors of relapse in small cell neuroendocrine carcinomas.
The use of minimally invasive RNU is linked to improved median OS and 90-day mortality in octogenarian patients with UTUC.
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.